# Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

Source: https://onco.cc/trials/nct06782685/  
OnCo record `nct06782685` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of cAPOX (capecitabine, oxaliplatin), bevacizumab, fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Dai, Guanghai, now recruiting.

## Summary

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV is a phase 1/2, randomised interventional study registered as NCT06782685 by Dai, Guanghai, with a registry enrolment figure of 138 participants, started 2024-06-23 and due to reach its primary completion in 2026-07. Interventions recorded: Irinotecan liposoma; oxaliplatin; bevacizumab; 5-FU; LV; Irinotecan Liposomal; Irinotecan Liposomal; Oxaliplatin. Conditions listed: Advanced Pancreatic Cancer (Part 1). Primary outcome: To explore the optimal dose combination of irinotecan liposomes plus oxaliplatin in the regimen of irinotecan liposomes plus oxaliplatin in bevacizumab. Pancreatic eligibility wording from the registry: "Patients with pancreatic cancer diagnosed by histopathology or cytology;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06782685
- Phase: 1/2
- Setting: Liposomal Irinotecan in Combination With Oxaliplatin and Bevacizumab Versus Liposomal Irinotecan in Combination With 5-FU/LV for the Second-line Treatment of Advanced Pancreatic Cancer
- Sponsor: Dai, Guanghai
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT06782685: https://clinicaltrials.gov/study/NCT06782685

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06782685.json